S&P 500 7,584.35 -0.33% NASDAQ 26,999.66 -0.35% DOW 50,959.81 -0.68% R2K 2,896.70 -1.20% VIX 16.27 +3.17%
Next Bullish Trade
ALNY Alnylam Pharmaceuticals, Inc. NMS
$287.98 +1.86 (+0.65%)
Pullback · -0.90σ
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $1.2B $0.2B $0.3B $0.0B 17.6% 23.0%
2025-12-31 $1.1B $0.2B $0.1B $0.1B 17.0% 12.0%
2025-09-30 $1.2B $0.3B $0.4B $0.3B 20.1% 29.5%
2025-06-30 $0.8B $-0.1B $-0.0B $0.1B -8.6% -2.1%
2025-03-31 $0.6B $-0.0B $0.0B $-0.1B -3.1% 3.0%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-30 1.99 1.47 +35.3%
2026-02-12 1.25 1.50 -16.5%
2025-10-30 2.90 1.75 +66.1%
2025-07-31 -0.51 -0.70 +27.1%
2025-05-01 -0.01 -0.37 +97.3%
2025-02-13 0.06 -0.14 +142.5%
2024-10-31 -0.50 -0.39 -26.7%
2024-08-01 0.56 -0.69 +181.1%
2024-05-02 -0.16 -0.63 +74.5%
2024-02-15 -0.77 -0.77 -0.2%
2023-11-02 1.74 -0.96 +281.9%
2023-08-03 -1.62 -1.34 -21.2%
2023-05-04 -1.06 -1.43 +25.7%
2023-02-23 -1.39 -1.48 +6.3%
2022-10-27 -1.58 -1.38 -14.6%
2022-07-28 -2.03 -1.36 -49.4%
2022-04-28 -1.49 -1.46 -2.1%
2022-02-10 -1.69 -1.26 -34.4%
2021-10-28 -1.51 -1.24 -21.4%
2021-08-03 -1.30 -1.28 -1.2%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
ALNY ★ $38B 72.4 20.7 9.0 47.3 35.7 80.8% 96.4% — 0.53%
LLY $964B 38.3 24.3 13.3 27.3 30.9 82.8% 55.5% 169.9% 0.95%
UNH $350B 29.0 18.5 0.8 18.5 3.6 18.8% 2.0% 0.7% 5.06%
JNJ $538B 25.9 17.6 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $287B 32.7 12.1 4.4 11.2 6.2 76.7% 4.9% — 4.90%
ABBV $384B 106.1 13.4 6.1 14.8 -57.7 72.0% 12.4% -46.2% 5.42%
PFE $145B 19.4 8.9 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.56%
TMO $176B 26.0 17.4 3.9 19.4 3.3 40.9% 6.2% 11.3% 3.14%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 56.34%

HolderShares% out
FMR, LLC 14,579,166 10.92%
Capital World Investors 10,802,348 8.09%
Blackrock Inc. 10,444,908 7.82%
Capital Research Global Investors 9,471,181 7.09%
Vanguard Portfolio Management LLC 6,491,280 4.86%
JPMORGAN CHASE & CO 6,323,752 4.74%
Vanguard Capital Management LLC 5,946,706 4.45%
T. Rowe Price Investment Management, 5,193,324 3.89%
State Street Corporation 3,322,698 2.49%
Geode Capital Management, LLC 2,660,385 1.99%

Insider activity · 90d

No insider trades for ALNY in last 90d.

Analyst estimates

yfinance
Low
$310.0
Mean
$445.81482
High
$566.0
Analysts
27

Consensus: buy (mean 1.76667). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
8-K 2026-05-27 8-K view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-22 PRIMARY DOCUMENT view ·
4 2026-05-14 PRIMARY DOCUMENT view ·
10-Q 2026-04-30 10-Q view ·
8-K 2026-04-30 8-K view ·
4 2026-04-07 PRIMARY DOCUMENT view ·
DEF 14A 2026-04-06 DEF 14A view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
4 2026-03-04 PRIMARY DOCUMENT view ·
8-K 2026-03-04 8-K view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-03-02 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
4 2026-02-17 PRIMARY DOCUMENT view ·
4 2026-02-17 PRIMARY DOCUMENT view ·
4 2026-02-17 PRIMARY DOCUMENT view ·
4 2026-02-17 PRIMARY DOCUMENT view ·
4 2026-02-17 PRIMARY DOCUMENT view ·
10-K 2026-02-12 10-K view ·
8-K 2026-02-12 8-K view ·
4 2026-01-14 PRIMARY DOCUMENT view ·
4 2026-01-14 PRIMARY DOCUMENT view ·
4 2026-01-14 PRIMARY DOCUMENT view ·
4 2026-01-14 PRIMARY DOCUMENT view ·
4 2026-01-14 PRIMARY DOCUMENT view ·
8-K 2026-01-12 8-K view ·
4 2026-01-07 PRIMARY DOCUMENT view ·
8-K 2025-12-11 8-K view ·
8-K 2025-12-03 8-K view ·
4 2025-12-01 PRIMARY DOCUMENT view ·
4 2025-11-19 PRIMARY DOCUMENT view ·
4 2025-11-14 PRIMARY DOCUMENT view ·
10-Q 2025-10-30 10-Q view ·
8-K 2025-10-30 8-K view ·
4 2025-10-03 PRIMARY DOCUMENT view ·
4 2025-10-03 PRIMARY DOCUMENT view ·
4 2025-10-03 PRIMARY DOCUMENT view ·
4 2025-10-03 PRIMARY DOCUMENT view ·
4 2025-10-03 PRIMARY DOCUMENT view ·
4 2025-10-03 PRIMARY DOCUMENT view ·
8-K 2025-10-03 8-K view ·

About

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight managemen…